Please use this identifier to cite or link to this item:
|Title:||LC-MS/MS proteomics analysis of biomarkers in Singapore breast cancer patients on doxorubicin treatment and MCF7 breast cancer derived cells||Authors:||Bahareh Haji Rasouliha||Keywords:||DRNTU::Engineering::Chemical engineering::Biotechnology||Issue Date:||2010||Source:||Bahareh, H. R. (2010). LC-MS/MS proteomics analysis of biomarkers in Singapore breast cancer patients on doxorubicin treatment and MCF7 breast cancer derived cells. Master’s thesis, Nanyang Technological University, Singapore.||Abstract:||Breast cancer is known as the most common cancer in women population, especially in developed countries. Improved prognosis and effective treatment are needed to reduce the mortality of the disease. Doxorubicin, a topoisomerase II-targeting chemotherapeutic drug has been widely used to treat breast cancer. The rapidly evolved proteomics techniques, especially LC-MS/MS analysis, has been used in protein profiling in body fluids as well as cells, which provide us with a deep comprehension in drugs mechanism and patients response to the treatment. This new method can be extended in biomarker identification to improve diagnosis and monitoring of treatment.||Description:||97 p.||URI:||https://hdl.handle.net/10356/47456||DOI:||10.32657/10356/47456||Rights:||Nanyang Technological University||Fulltext Permission:||open||Fulltext Availability:||With Fulltext|
|Appears in Collections:||SCBE Theses|
Items in DR-NTU are protected by copyright, with all rights reserved, unless otherwise indicated.